Kanabo Group Plc Share Price London S.E.
Equities
SOP
GB00BYQCS703
Pharmaceuticals
Sales 2021 | 73K 91.4K 7.63M | Sales 2022 | 603K 755K 63.04M | Capitalization | 8.04M 10.06M 840M |
---|---|---|---|---|---|
Net income 2021 | -4M -5.01M -418M | Net income 2022 | -6M -7.51M -627M | EV / Sales 2021 | 648 x |
Net cash position 2021 | 4.5M 5.63M 470M | Net cash position 2022 | 3.01M 3.77M 315M | EV / Sales 2022 | 8.33 x |
P/E ratio 2021 |
-9.98
x | P/E ratio 2022 |
-1.15
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 50.93% |
Managers | Title | Age | Since |
---|---|---|---|
Avihu Tamir
CEO | Chief Executive Officer | - | - |
Assaf Vardimon
DFI | Director of Finance/CFO | 46 | - |
Ophir Shimshi
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ian Mattioli
CHM | Chairman | 62 | 09/23/09 |
David Tsur
BRD | Director/Board Member | 73 | 28/21/28 |
Sharon Malka
BRD | Director/Board Member | 51 | 04/23/04 |
1st Jan change | Capi. | |
---|---|---|
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |